Zhongguo quanke yixue (Sep 2023)
Effects of Different Neoadjuvant Chemotherapy Regimens on Immune Indicators and Tumor Microenvironment in HER-2-positive Breast Cancer Patients
Abstract
Background Breast cancer is a common clinical malignant tumor, which seriously affects the health of women. Although the current targeted therapy system for breast cancer is well established, the difference in clinical efficacy between double-target therapy and single-target therapy remains unclear.Objective To explore the effects of different neoadjuvant chemotherapy regimens on the immune indicators and tumor microenvironment in HER2-positive breast cancer patients.Methods A total of 92 patients with HER-2-positive breast cancer admitted to Changzhou No.2 People's Hospital Affiliated to Nanjing Medical University from September 2017 to September 2021 were collected and randomly divided into the study group (trastuzumab+patuzumab+docetaxel therapy, n=46) and the control group (trastuzumab+docetaxel therapy, n=46) . The clinical efficiency rate and control rate, the changes of inflammatory factors levels and immunological indicators were compared between the two groups.Results The clinical efficiency rate and control rate after treatment of the study group were higher than those of the control group (P<0.05) . The peripheral blood CD3+, CD4+ and CD4+/CD8+ levels were higher and CD8+ levels was lower in the study group than those in the control group after treatment (P<0.05) , the levels of TNF-α, IFN-γ, IL-6 and IL-8 in the study group were lower than those in the control group (P<0.05) . The percentages of PD-L1-positive cells≥25% and PD-1-positive cells≥65% in the study group were higher than those in the control group, while the percentage of FoxP3-positive cells≥0.45% in the study group was lower than that in the control group.Conclusion Neoadjuvant chemotherapy of trastuzumab + patuzumab + docetaxel can effectively improve the immune indicators and tumor microenvironment of HER-2 positive breast cancer patients.
Keywords
